Celtic Pharma Development Services: Clinical Trials

5 trials sponsored by Celtic Pharma Development Services, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

3 completed, 2 terminated. 5 Phase 2, 1 Phase 1.

By phase and status

PhaseTrialsStatus
Phase 25Completed 3, Terminated 2
Phase 11Terminated 1

Follow Celtic Pharma Development Services: new trials by email

Trials (filtered) newest first · largest first

All 5 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Multisite Controlled Trial of Cocaine Vaccine
TA-CD Vaccination, Placebo Injection - Cocaine Dependence
Phase 2CompletedBaylor College of Medicine3002010-08-012017-03-15
Tolerability Study of Xerecept® in Pediatric Patients
XERECEPT - Brain Edema, Brain Tumor
Phase 1 / Phase 2TerminatedCeltic Pharma Development Services152010-06-012013-07-30
TDT 067 Open Label Multi-Dose Onychomycosis Study
TDT067 and Lamisil - Onychomycosis
Phase 2CompletedCeltic Pharma Development Services272009-12-012013-02-13
Imaging Study of XERECEPT® Treatment for Peritumoral Brain Edema (PBE)
Xerecept - Peritumoral Brain Edema, PRIMARY MALIGNANT and METASTATIC BRAIN TUMORS
Phase 2TerminatedPharmaNet602008-11-012009-01-09
Study of TA-NIC to Assess the Efficacy and Safety of the Vaccine as an Aid to Smoking Cessation
TA-NIC, Placebo - Smoking
Phase 2CompletedCeltic Pharma Development Services5222007-05-012011-06-08

Conditions studied

Brain Neoplasms (2)  ·  Brain Edema (1)  ·  Cocaine-Related Disorders (1)  ·  Edema (1)  ·  Onychomycosis (1)  ·  Smoking (1)  ·  Smoking Cessation (1)

Interventions

Corticotropin-Releasing Hormone (1)  ·  TA-NIC (1)  ·  Terbinafine (1)

Countries

United States (3)

Top investigators

Eduardo Tschen, MD (1)  ·  Stewart Goldman, MD (1)  ·  Thomas R Kosten, M.D. (1)

Results publications

PMID 19805702, PMID 24793366

NIH funding

R01DA025223 (1)